Skip to main content
Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: An integrated view of the role of miR-130b/301b miRNA cluster in prostate cancer

Fig. 4

Association between the expression of miR-130b and clinical characteristics in the TCGA-PRAD cohort. a Comparison of pathological T-stage in patients with levels of miR-130b in the upper and lower deciles of expression (n = 96, Fisher’s exact test). b Level of miR-130b in patients without (R = 0 median = 5.00) or with residual tumor (R = 1 median = 5.65) (n = 456, Mann–Whitney test). c Level of miR-130b in PrCa tissue of patients in which the primary therapy outcome is complete remission indicated as Remission (median = 4.45) or Disease-including stable and progressive disease—(median = 5,36) (n = 438, Mann–Whitney test)

Back to article page